GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Operating Margin %

BioNTech SE (BSP:B1NT34) Operating Margin % : 40.43% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. BioNTech SE's Operating Income for the three months ended in Dec. 2023 was R$3,195 Mil. BioNTech SE's Revenue for the three months ended in Dec. 2023 was R$7,903 Mil. Therefore, BioNTech SE's Operating Margin % for the quarter that ended in Dec. 2023 was 40.43%.

The historical rank and industry rank for BioNTech SE's Operating Margin % or its related term are showing as below:

BSP:B1NT34' s Operating Margin % Range Over the Past 10 Years
Min: -167.13   Med: -17.08   Max: 78.66
Current: 23.64


BSP:B1NT34's Operating Margin % is ranked better than
91.13% of 1026 companies
in the Biotechnology industry
Industry Median: -177.195 vs BSP:B1NT34: 23.64

BioNTech SE's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

BioNTech SE's Operating Income for the three months ended in Dec. 2023 was R$3,195 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was R$5,038 Mil.


BioNTech SE Operating Margin % Historical Data

The historical data trend for BioNTech SE's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Operating Margin % Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -167.13 -17.08 78.66 71.08 23.68

BioNTech SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.93 57.09 -300.95 9.15 40.43

Competitive Comparison of BioNTech SE's Operating Margin %

For the Biotechnology subindustry, BioNTech SE's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNTech SE's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Operating Margin % falls into.



BioNTech SE Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BioNTech SE's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=4831.406 / 20406.037
=23.68 %

BioNTech SE's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=3195.289 / 7902.731
=40.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNTech SE  (BSP:B1NT34) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BioNTech SE Operating Margin % Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNTech SE (BSP:B1NT34) Business Description

Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines